天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Pomalidomide-PEG6-butyl iodide

Pomalidomide-PEG6-butyl iodide Struktur
1835705-74-2
CAS-Nr.
1835705-74-2
Englisch Name:
Pomalidomide-PEG6-butyl iodide
Synonyma:
Pomalidomide-2-2-2-2-2-2-6-I;Pomalidomide-PEG6-butyl iodide;Pomalidomide-PEG?-butyl iodide;N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-24-iodo-3,6,9,12,15,18-hexaoxatetracosanamide;Acetamide, N-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]-2-[(21-iodo-3,6,9,12,15-pentaoxaheneicos-1-yl)oxy]-;N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-24-iodo-3,6,9,12,15,18-hexaoxatetracosanamide, Crosslinker?E3 Ligase ligand conjugate, Pomalidomide-2-2-2-2-2-2-6-I, Protein degrader building block for PROTAC? research, Template for synthesis of targeted protein degrader
CBNumber:
CB04919986
Summenformel:
C31H44IN3O11
Molgewicht:
761.6
MOL-Datei:
1835705-74-2.mol

Pomalidomide-PEG6-butyl iodide Eigenschaften

Siedepunkt:
853.5±65.0 °C(Predicted)
Dichte
1.448±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
L?slichkeit
DMSO : 100 mg/mL (131.30 mM; Need ultrasonic)
pka
10.68±0.40(Predicted)
Aggregatzustand
Solid
Farbe
White to off-white

Sicherheit

Pomalidomide-PEG6-butyl iodide Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Protein degrader builiding block Pomalidomide-PEG6-butyl iodide enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a Cereblon (CRBN)-recruiting ligand, a linker with both hydrophobic and hydrophilic moieties, and a pendant iodoalkane for reactivity with a nucleophilic group on a target ligand. Because even slight alterations in ligands and crosslinkers can affect ternary complex formation between the target, E3 ligase, and PROTAC, many analogs are prepared to screen for optimal target degradation. When used with other protein degrader building blocks with a pendant iodo group, parallel synthesis can be used to more quickly generate PROTAC libraries that feature variation in crosslinker length, composition, and E3 ligase ligand.

Pomalidomide-PEG6-butyl iodide Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Pomalidomide-PEG6-butyl iodide Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 17)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 32161 58
TargetMol Chemicals Inc.

support@targetmol.com United States 38631 58
Xian confluore Biological Technology Co., Ltd.
+86-15680926068 +86-15680926068
1924344760@confluore.cn China 2996 58
Aladdin Scientific
+1-+1(833)-552-7181
sales@aladdinsci.com United States 52924 58
Sigma-Aldrich 021-61415566 800-8193336
orderCN@merckgroup.com China 51456 80
Shanghai EFE Biological Technology Co., Ltd. 021-65675885 18964387627
info@efebio.com China 9806 58
Xi'an Confluore Biological Technology Co., Ltd. +86-156-80926068 +86-15680926068
1924344760@qq.com China 4825 58
Jilin Province Woda Biotechnology Co., Ltd. 13504435624
1927928688@qq.com China 1460 58
Shanghai Haohong Pharmaceutical Co., Ltd. 4008210725 4008210725
malulu@leyan.com China 54987 58
Zhengzhou convergence chemical co., LTD 0371-0371-55153829 18003835034
2853979819@qq.com China 9732 58

  • Pomalidomide-PEG6-butyl iodide
  • Pomalidomide-2-2-2-2-2-2-6-I
  • Acetamide, N-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]-2-[(21-iodo-3,6,9,12,15-pentaoxaheneicos-1-yl)oxy]-
  • N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-24-iodo-3,6,9,12,15,18-hexaoxatetracosanamide, Crosslinker?E3 Ligase ligand conjugate, Pomalidomide-2-2-2-2-2-2-6-I, Protein degrader building block for PROTAC? research, Template for synthesis of targeted protein degrader
  • Pomalidomide-PEG?-butyl iodide
  • N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-24-iodo-3,6,9,12,15,18-hexaoxatetracosanamide
  • 1835705-74-2
Copyright 2019 ? ChemicalBook. All rights reserved